PSEN1 and amyloidosis: In support of reduced vulnerability to amyloidosis-associated neurotoxicity, subchronic (3 weeks) exendin-4 treatment has been shown to reduce soluble β-amyloid levels, to lower cortical amyloid plaque load and improve memory performance in a double transgenic APP/PS1 mouse model of amyloidosis [21].